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Abstract
Background: Lymph node invasion is one of the most powerful clinical factors in cancer prognosis. However,
molecular level signatures of their correlation are remaining poorly understood. Here, we propose a new approach,
monotonically expressed gene analysis (MEGA), to correlate transcriptional patterns of lymph node invasion related
genes with clinical outcome of breast cancer patients.
Results: Using MEGA, we scored all genes with their transcriptional patterns over progression levels of lymph node
invasion from 278 non-metastatic breast cancer samples. Applied on 65 independent test data, our gene sets of
top 20 scores (positive and negative correlations) showed significant associations with prognostic measures such as
cancer metastasis, relapse and survival. Our method showed better accuracy than conventional two class
comparison methods. We could also find that expression patterns of some genes are strongly associated with
stage transition of pathological T and N at specific time. Additionally, some pathways including T-cell immune
response and wound healing serum response are expected to be related with cancer progression from pathway
enrichment and common motif binding site analyses of the inferred gene sets.
Conclusions: By applying MEGA, we can find possible molecular links between lymph node invasion and cancer
prognosis in human breast cancer, supported by evidences of feasible gene expression patterns and significant
results of meta-analysis tests.
Background
T h ep r e s e n c eo fl y m p hn o d ei n v a s i o ni so n eo ft h e
strongest indicators for prognoses of distant metastasis
and survival in most cancers [1,2]. In the multi-step pro-
cess of cancer metastasis development, invasion into a
vascular or a lymphatic system has generally been
believed to be a key step of tumor cell dissemination
[3-5]. Once tumor cells acquire abilities of intravasation
and survival in an unfavorable vascular environment,
they circulate around the whole body parts to form new
tumors at the secondary site [6]. While the exact
mechanisms of cancer metastasis through blood vessels
and lymph nodes are still being studied, it is necessary
to explain the processes in a genetic level as a key factor
of cancer patients’ prognosis.
Many researchers have devoted their efforts to under-
stand lymph node invasion in breast cancers, because
regional lymph nodes are frequently observed as the
first site of metastasis [7]. Survival analyses with clinical
features showed that lymph node status is generally
marked as a top significant factor among conventional
clinical features [8-10]. Studies of finding molecular
markers using genome-wide expression profiles identi-
fied various genetic signatures for prediction of lymph
node and distant metastasis [11-19]. However, the asso-
ciations between conventional clinical features including
tumor size, lymph node involvement and distant metas-
tasis (TNM staging [20]) and prognosis are not yet
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any medium, provided the original work is properly cited.identified in a genetic level. Moreover, the existence of a
common gene set for lymph node metastasis in a tran-
scriptional level is unclear [21].
So far, t-test based differential expression analysis or
clustering methods between lymph node negative and
positive samples have been used to detect corresponding
gene sets [17-19,21]. Although these methods are
straightforward and intuitive, there are several inherent
problems in them. First, direct comparison within two
classes (lymph node negatives and positives) may sim-
plify the subtle changes over cancer progression.
Usually, four-stage pathological N (N0~N3) is used to
indicate the degree of lymph node invasion in breast
cancer; N0 denotes no lymph node invasion observed.
Regarding the expression values as longitudinal data to
find patterns over lymph node progression might benefit
from utilizing known biomedical information. For
instance, a gene whose expression is significantly high
only at a certain stage (e.g. N2) is hardly accepted as a
closely related gene from current metastasis model.
However, a two-class comparison (e.g. N0 vs. others)
would mark it differently expressed. Second, the effect
of a factor (e.g. lymph node invasion) should be sepa-
rated from the effect of the others (e.g. tumor size or
histological subtype). These factors are generally not
independent and will lead to false findings unless care-
fully analysed. And, the validation of inferred gene sig-
natures should be performed on sufficient number of
independent sets in a strict statistical manner. The data
statistics and characteristics including inherent biases
should be recognized, appropriately treated and be prop-
erly analyzed in a meta-analytic way.
There are several statistical models applicable for mul-
tivariate correlation scoring (instead of two-class based
scoring). Linear/Non-linear (multiple) regression and
analysis of variance models (two-way ANOVA and
MANOVA) have been widely used in various fields.
Both models (linear and non-linear), however, have a
few weaknesses; a gene expression pattern over lymph
node progression is not necessarily linear, and the data
has too few time points to be assessed in a non-linear
way. ANOVA models are usually used to test if there is
a significant difference among the mean values, so it is
not robust to inconsistent fluctuations of expression
values. In time series analyses, autoregressive moving
average model and its variants (ARMA, ARMAX and
ARIMA) are widely used especially in electronic engi-
neering and system identification fields, and some unit
root tests (for stationarity test in time series including
Augmented Dickey Fuller test [22]) have been used in
statistics and econometrics as well. However, there are a
few difficulties in adapting these models to our problem;
the number of time points is very few, intervals are not
regular and the stage is a pseudo-time. After reviewing
the conventional models, we developed a new multivari-
ate correlation measure specially designed for non-linear
and small data point analysis. Nevertheless, the conven-
tional models were applied as well and tested to com-
pare with our measure and two-class based analyses.
Our method, monotonically expressed gene analysis
(MEGA), scores gene expression patterns with their
non-linear monotonicity over a stage progression of
interest. It accumulates all the normalized expressional
differences between two consecutive stages (see Meth-
ods). If the direction of expressional change is consis-
tently positive or negative, the score increases;
otherwise, the sum of differences will be cancelled out.
Because there are two non-independent factors (stage T
and N), one variable should be fixed while the other
variable is being used. In MEGA, a two dimensional
matrix is constructed, each dimension of which is com-
posed of four points (N0~N3 and T1~T4, T0 is
excluded due to the lack of data) generating totally 16
data points per a gene. So, applying the scoring function
to each row or column represents calculating the cumu-
lative expressional changes over one factor while the
other is fixed. MEGA also has a weight parameter to
emphasize a specific stage transition (e.g. N1® N2) to
capture genes activated or repressed in a particular time
range. After calculating scores, top k genes are collected
and named N-wise monotonically expressed genes (N-
MEG) or T-wise monotonically expressed genes (T-
MEG) depending on which factor is used for the analy-
sis. Validation of inferred gene sets can be done in a ret-
rospective way to see how accurately the gene sets
classify prognostic outcomes in other independent data.
P-values from each test data are integrated by meta-ana-
lysis to report more confident accuracy of the gene sets.
This is basically one of the most unbiased ways for eval-
uating usefulness of inferred gene signatures.
If the gene sets show consistence and confident accu-
racy, a series follow-up analysis can be used for reason-
ing biological meaning (e.g. common pathways or
transcription factors). First, gene set analysis can dis-
cover some biological pathways involving in metastasis
progression. Considering pathways instead of individual
genes as an acting unit of biological phenomena
explains how different gene sets are sometimes asso-
ciated with same conditions. And we can find more suc-
cinct way to describe the whole processes. Second, the
fact that the genes show similar expression patterns as
the cancer metastasis progresses leads us to a hypothesis
that some common transcription factors play a crucial
role in the process. Here, all the genes are not necessa-
rily causative; rather, they are effect from changes of a
fewer number of genes in upper hierarchy. In this case,
finding frequently represented motifs from the promoter
regions of the gene sets might be a good analysis for
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more powerful information in practical applications
such as pharmaceutical research and patient treatment.
Results
Totally four gene sets of size 20 are constructed from
278 breast tumor gene expression data (expO database)
by applying monotonically expressed gene analysis
(MEGA). They are N-wise monotonically expressed
genes (N-MEG) and T-wise monotonically expressed
genes (T-MEG), which are further divided into positive
and negative correlation sets. Given these four gene sets
(N-MEG+, N-MEG-, T-MEG+, and T-MEG-), we tested
on65 independent breast cancer prognosis data sets
downloaded from ONCOMINE database (See Methods
for details) how much the expression values of the
genes are correlated with prognostic outcomes.
Lymph node-wise monotonically expressed genes (N-
MEG)
The result of meta-analysis test with N-MEG+ and N-
MEG- is shown in Figure 1. Two gene sets are divided
by the vertical separator. Three major analysis types
(PRG, STG, and GRD) and seven minor analysis types
are denoted in the first and second columns. Each row
corresponds to an experiment and each column corre-
sponds to a gene. So a value in a cell is a p-value of a
gene in the corresponding experiment. Cells are colored
blue when the genes are significantly up-regulated at the
study, yellow when down-regulated, black when not sig-
nificantly regulated, and grey when the genes could not
be found in the corresponding experiments; here, up-
regulation means genes are up-regulated in bad-prog-
noses, higher stages, and higher grades.
It is easily shown that N-MEG+ genes are positively
correlated with worse prognoses, higher tumor stages
and higher tumor grades. Similarly, N-MEG- is nega-
tively correlated. From the p-value matrix, we can calcu-
late integrated p-values using three meta-analysis
methods over ten test classes (Figure 2). It is easily
found that the N-MEG is highly significant in all types
of prognosis analyses (p-values less than 10
-14 in any
methods). Except the test for stage M (current status of
metastasis), all p-values were less than 0.01. The study
of stage M is designed for elucidating differences of
gene expression profile between primary tumors and
metastatic tumors. The conceptual difference from the
prognosis study of metastasis is that while the former
describes the status of ‘metastasis occurred’,t h el a t t e r
describes ‘metastasis will occur’.T h er e s u l t so fs t a g eN
and stage T were intermediately significant; five of the
seven studies in the stage N are two class comparisons
(N0 vs. others).Correlations with the tumor grade stu-
dies were extremely significant. It is also shown that the
Stouffer’s Z method gives relatively more conservative
results. As the Stouffer’s Z method has been proven to
be more robust to a few extreme values [23] and cor-
rectable here (see Methods), we will use the corrected
version of this method for rest of the study.
I nac o m p a r i s o nw i t hg e n es e t sf r o mp r e v i o u sw o r k ,
the N-MEG showed the highest association with cancer
prognoses (Figure 3).Gene sets from a multiple regres-
sion and a two-way ANOVA model followed it and
other two gene sets (Suzuki et al and Ellsworth et al)
showed relatively lower significance. This result implies
that the pattern based methods (MEGA, two-way
ANOVA and multiple regression models) are more
effective than two class direct comparison methods (t-
test and clustering) in finding prognosis associated
genes. On the other hand, ANOVA and Suzuki set
showed the best score with the N stage. Like we already
mentioned, most of the existing N stage test sets are
based on a t-test within two classes, which is the same
method as what Suzuki et al used. In other analysis
types including M and T stage grouping and tumor
grade, we could not find significant differences among
five methods. Abba set was also tested even though the
gene set was already had a selection step using prog-
nosis data (selecting 46 top ranked genes from 300
genes, see Methods). The test showed that our gene set
was comparable to it (better in metastasis, relapse and
overall prognosis) in spite of a significant degree of
unfairness.
Overall aspects of gene expression progression along
t h eNs t a g eg i v ee x p l i c i te x p l a n a t i o n so fd i f f e r e n c e s
among the candidate gene sets (Figure 4). In the N-
MEG and multiple regression model-based gene sets
show consistent increase or decrease along the N stage
independent to the T stage (Figure 4A and 4B). How-
ever, gene sets from two class direct comparison meth-
ods (t-test and Mann-Whitney test) show certain degree
of inconsistency and discrepancy between lymph node
phenotypes and gene expression patterns (Figure 4D,
4E, and 4F). This result shows that those gene sets
(lymph node positive vs. negative) may contain false
positives from abstracting detailed pattern information,
and also implicates the reason why N-MEG showed
relatively high significance in the prognosis test.
Classification and survival analysis
To show the classification power of the N-MEGs, we con-
ducted a test for 5-year metastasis free survival data from
Wang et al [15]. Because the meaning of N-MEG+ and N-
MEG- is so clear, we scored the sum of row-normalized z-
scores of corresponding genes; adding for 20 N-MEG+
genes and subtracting for 20 N-MEG- genes. For the 286
primary breast samples (91 metastasis in 5-years), the
mean score was nearly zero (6.5x10
-13) and the standard
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bigger than the mean plus one standard deviation, 37 had
metastasis in 5-years giving 0.35 of sensitivity and 0.92 of
specificity. The overall accuracy was 0.71. An ROC curve
was drawn to compare the N-MEGs with other gene sets
(Figure 5A). The N-MEGs showed the best classification
power. Interestingly, while the two statistical approaches
using stage progression (multiple regression and two-way
ANOVA) managed to prove a certain degree of usefulness,
the studies using two class comparisons did not. Although
the result may be further improved by other fancy classi-
fiers with optimization procedures, we can tentatively con-
clude that observing the signatures of stage progression
gives better results. A set of area under curve (AUC) were
Figure 1 N-MEG with their meta-analysis test result. H e r e ,2 0N - M E G +a n d2 0N - M E G -g e n e sa r etested. Each column corresponds to a
specific gene, and each row to an experiment in the ONCOMINE test set. Test set of 65 experiments are classified into three major classes (PRG,
STG, and GRD), each of which are subdivided into several minor classes. Blue color denotes up-regulation, and yellow color denotes down-
regulation. Experiments with an asterisk (*) denote they used the expO database, and were excluded from further analyses. PRG=prognosis,
MP=metastatic prognosis, RLP=relapse prognosis SVP=survival prognosis, STG=stage, M=M stage, N=N stage, G=stage grouping, T=T stage,
GRD=tumor grade.
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~ 0.757 in 95% confidence limits). To conduct a survival
analysis we divided the all 286 patients into three groups
of equal size (n=95 for good and poor group, 96 for inter-
mediate group). It is shown that the three groups have
distinct metastasis free survival and hazard rate in Kaplan
Meier estimation (Figure 5 C and D).
T-wise monotonically expressed genes (T-MEG) and
comparison with N-MEG
T-MEG (n=40, 20 T-MEG+ and 20 T-MEG-) were also
significantly correlated with breast cancer prognosis
including metastasis and relapse, but the significance
was generally worse than N-MEG (Table 1). In the
prognosis of metastasis studies, both of the T-MEG+
and T-MEG- were significant (p-values of 4.3x10
-8
and3.1x10
-3respectively), but they were not as effective
as N-MEG (p-values of 1.2x10
-15 and1.4x10
-6). This
result agrees with the previously known pathological
facts; both of the degree of lymph node invasion and
tumor size are important in predicting metastasis prob-
abilities, while the former gives more direct evidences.
We can also notice that tumor size related gene were
either not significant (in prognosis of survival and
tumor stages) or less significant than lymph node inva-
sion related genes (in prognosis of relapse and tumor
grade).
The distinct characteristics between the two tumoral
features might be tumor tissue specific. Breasts are not
essential organs for personal survival. So even though a
tumor has grown to be large, the cancer is not a fatal
disease unless the tumor has been spread to other
organs. In this case, mastectomy would be effective for
Figure 2 P-values of N-MEG over ten analysis types. Each line
denotes a different kind of meta-analysis method. Except the ‘stage
M’ class, all the p-values are less than 0.01 (and extremely low in
prognosis analyses). Each p-value was calculated by multiplying two
p-values from 20 up and 20 down genes.
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Figure 3 Comparison with previous studies. Each value corresponds to a sum of log-odd scores from up and down regulated gene sets. In
prognosis analyses, pattern based methods (MEGA, multiple regression and ANOVA models) showed better results than two-class comparison
methods (Paired t-test in Suzuki and Mann-Whitney test in Ellsworth). N-MEG (blue) showed the best significance among all the gene sets.
Instead, N-MEG and a multiple regression set showed relatively low significance in tumor stage data; probably because most of the N stage test
sets used two-class comparison methods. Values in tumor grade analyses were scaled down to 1/10 for better presentation of the graph. N-MEG
= N-wise monotonically expressed genes, MR = multiple regression, 2ANOVA = two-way ANOVA.
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nosis is a result of complex and stochastic activities
among cellular processes, we can conclude this tendency
would be valid for other non-essential organs.
Genes related to specific N stage transitions
We further tested the significance of genes related to
specific steps of lymph node invasion progression by
altering a leaping factor b. The leaping factor was set to
10 and applied to three different steps (N0®N1,
N1®N2, and N2®N3) with a factor remains to be
zero. These gene sets are N-wise monotonically
expressed genes with a leaping at a specific stage transi-
tion A®B( N - M E G
A®B: here, N-MEG
0®1,N - M E G
1®2,
and N-MEG
2®3 respectively). Interestingly, we found
significant discrepancy among lymph node invasion pro-
gression steps (Table 2). Genes which were significantly
up or down regulated in the N1®N2 progression (N-
MEG
1®2) were of no significance in most of the prog-
nosis and tumor stage studies (p-values > 0.01). Instead,
N-MEG
0®1 and N-MEG
2®3 were significant in most of
the studies including prognosis of metastasis, prognosis
of relapse, prognosis of survival and tumor grade.
Firstly, we expected that N-MEG
0®1 would be more
informative than N-MEG in the other stage transitions.
Because, it is thought that if a set of tumor cells acquire
high motility to migrate and intravasate into lymph
nodes, dissemination of tumor cells over the larger parts
of lymph nodes would follow spontaneously [5]. But the
result of meta-analysis test represents that there would
Figure 4 Aspects of gene expression patterns. Top ranked genes from four different methods are shown (A: N-MEG, B: multiple regression, C:
two-way ANOVA, D: Suzuki set, E: Ellsworth set, and G: Abba set). Genes in the first row are up-regulated genes in lymph node positive samples
in each study, the second row are down regulated genes (except in B; ANOVA does not give directional results). Lymph node progression is
denoted in X-axis, and the relative expression values against normal breast samples are denoted in Y-axis (in log 2 based fold change). Four
different colors are used to discriminate different tumor sizes (T stage 1 to 4). Expression patterns of two genes from N-MEG and multiple
regression (FLJ32549, AKR1D1, TMEM65 and MGC35361) show consistent increase (top row) or decrease (bottom row) in all tumor sizes, while
top-ranked genes from other studies (D~F) show either inconsistency among different tumor sizes (D up, E and F up) or disagreement over
phenotypic traits (D down, E down, and F up). We can see that the multiple regression model find more linear relationships (B) and ANOVA set
contains significant fluctuations (C).
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step of lymph node invasion before raising distant
metastasis.
To inspect the characteristics of N-MEG
0®1 and N-
MEG
2®3, we chose 200 genes from each gene set (100
positive and 100 negative genes in N-MEG
0®1 and N-
MEG
2®3) and compared them each other. We found
that there were few overlaps between two gene sets; no
overlap in top 20 genes, and only two overlaps in 200
genes. But in the gene function analysis using Gorilla
[24], both gene sets were enriched in the immune
response GO terms (p-values ~ 1.0×10
-4). Where the
immune response is a well-known process affecting
lymph node invasion [25-27], it is convincing that both
gene sets are distinct but closely related to lymph node
invasion by connected pathways (see Additional Files 1
and 2 for full enrichment map).
Pathway analysis of N-wise progression
To observe changes of pathways in N-wise progression,
we applied Gene Set Enrichment Analysis (GSEA) [28]
to N-MEG. All 20,073 genes were sorted by their LE’
scores in descendant order. And the sorted list was ana-
lyzed by the GSEA Preranked test using 1,186 curated
Figure 5 Classification and survival analysis using N-MEG genes. (A) An ROC curve shows that the genes from MEGA analysis (N-MEG) have
the strongest classification power among other candidate lymph node related genes. (B) Areas under ROC curve (AUC) denote the statistical
measurement of the classification power. Note that the genes from previous two-class comparisons hardly prove their usefulness in classification;
but the result may differ when conducted in other classification methods. (C and D) Three risk groups (good, intermediate and poor) show
distinct survival and hazard functions in Kaplan-Meyer diagrams. AUC=area under curve, Std. Error=standard error, Asym. Prob.=Asymptotic
probability, LCL=lower confidence limit, UCL=upper confidence limit.
Table 1 Comparison of N-MEG and T-MEG in a meta-analysis test
Analysis N-MEG (n=40) T-MEG (n=40)
N-MEG+ (n=20) N-MEG- (n=20) T-MEG+ (n=20) T-MEG- (n=20)
Metastasis Prognosis 1.2x10
-15 1.4x10
-6 4.3x10
-8 3.1x10
-3
Relapse Prognosis 7.9x10
-27 7.8x10
-6 7.6x10
-4 2.1x10
-7
Survival Prognosis 5.7x10
-13 0.21 0.41 0.013
Overall Prognosis 9.4x10
-51 1.9x10
-8 1.5x10
-6 1.1x10
-9
Stage M 0.38 0.28 0.91 2.8x10
-4
Stage N 0.017 0.10 0.15 0.57
Stage T 2.1x10
-3 0.074 0.098 0.15
Stage G 0.063 7.2x10
-3 0.93 0.18
Overall Stage 2.1x10
-4 1.2x10
-3 0.46 0.075
Tumor Grade 1.3x10
-104 1.3x10
-8 2.3x10
-8 6.0x10
-10
N-MEG showed better significance than T-MEG. Generally speaking, N-wise progression gives more information than T-wise progression in cancer prognosis.
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turbations). In the N-MEG+ genes, we found that top
ranked enriched pathways were closely related to T cell
activities, cell differentiation and wound healing path-
ways (Table 3). It is previously known that immune
response has dual role in tumor initiation and progres-
sion (reviewed in [26]) – inhibition of tumor growth by
antitumor cytotoxic T-cell activities (reviewed in [29]),
and promotion of tumorigenesis, invasion and metasta-
sis by arising chronic inflammatory environment
[30-32]. Recently, DeNardo et al found that CD4+ T
cell promotes lung metastasis of breast cancer through
macrophages [33]. These evidences are in concordance
with our N-MEG+ result by supporting that mainte-
nance or increase of N-wise gene expression is closely
correlated with lymph node invasion and poor prog-
nosis. It is also well known that a serum response of
fibroblasts including wound healing pathways efficiently
predicts cancer progression [34]. Other two gene sets in
the Table 3 are from previously studied result about
general differentiation of tumor cells (tumor grade) and
prognosis, which support that the N-MEG+ are nega-
tively correlated with differentiation and prognosis.
Common TF binding site prediction for N-MEG
Because the N-MEG+ and N-MEG- are already selected
from their expression patterns along the lymph node
invasion progression, we can hypothesize that they are
co-regulated by several core transcription factors. To
find candidate common transcriptional regulators, we
analyzed upstream regions of the N-MEG and selected
significantly over-represented motif binding sites using
Pscan program [35]. We selected top 20, 30, and 50 N-
MEG and obtained matching mRNA RefSeq sequences
from DAVID database [36,37]. By running Pscan on
[-450, +50] upstream regions onto the JASPAR database
[38], we found that ELK4 and ELK1 binding sites were
significantly over-represented (p-values 7.8×10
-7 and
8.1×10
-6 respectively, data shown in Figure 6). ELK4 and
ELK1 (E26 Like Transcription Factor) are previously
known as members of ternary complex factor (TCF)
subfamily, which forms a ternary complex by binding to
the serum response factor and the serum response ele-
ment in a promoter region of the c-fos proto-oncogene
[39] (SAP1 is a previous name for ELK4). This finding
supports the results of the pathway analyses in the pre-
vious section implicating that ELK4 based serum
response mechanism might be a driving force for breast
cancer lymph node invasion and metastasis.
We also conducted the same analysis with N-MEG
0®1
and N-MEG
2®3 (b=10). While there was no significant
common binding sites in N2®N3 progression, we found
STAT1, IRF2, and IRF1 can be common binding tran-
scription factors in 50 N-MEG
0®1 (p-values of 4.4×10
-
Table 2 Comparison of stage transition specific genes
Analysis N-MEG
0®1 (n=40) N-MEG
1®2 (n=40) N-MEG
2®3 (n=40)
+-+-+-
MP 2.8×10
-4 0.13 0.24 0.13 5.7×10
-12 3.8×10
-11
RLP 7.7×10
-7 1.0×10
-15 0.13 0.084 4.8×10
-11 2.3×10
-6
SVP 5.9×10
-4 0.03 0.75 0.53 1.2×10
-10 1.4×10
-5
OVP 1.2×10
-11 9.3×10
-13 0.24 0.08 7.8×10
-29 2.0×10
-17
STM 0.042 0.14 0.97 0.30 0.043 0.035
STN 0.030 3.5×10
-6 0.04 0.068 9.4×10
-4 0.06
STT 1.8×10
-3 2.4×10
-10 0.12 0.069 5.9×10
-7 0.75
STG 1.1×10
-5 6.9×10
-9 0.01 0.015 0.11 0.53
Overall Stage 6.6×10
-8 2.3×10
-20 4.2×10
-3 1.4×10
-3 7.0×10
-8 0.15
Tumor Grade 2.1×10
-16 2.9×10
-22 7.2×10
-6 0.48 1.1×10
-42 1.7×10
-58
N-MEG
2®3 (b=10) showed the best significance in cancer prognosis test sets. While N-MEG
0®1was also significantly associated with prognosis and some stages,
N-MEG
1®2 showed surprisingly insignificant results. MP=prognosis of metastasis, RLP=prognosis of relapse, SVP=prognosis of survival, OVP=overall prognosis,
STM=stageM, STN=stageN, STG=stageG.
Table 3 Enriched pathway analysis of N-MEG+ using GSEA
R Gene Set Name Size ES NES P FD Gene Set Description
1 WIELAND_HEPATITIS_B_INDUCED* 96 0.62 3.10 0 0 Up-regulated with adaptive T cell activities in viral clearance
2 LEE_TCELLS3_UP* 103 0.63 3.05 0 0 Up-regulated in immature T cell in CD4+ T cell differentiation
3 CANCER_UNDIFF_META_UP
@ 69 0.65 3.05 0 0 Up-regulated in undifferentiated tumor cells
4 SERUM_FIBROBLAST_CELLCYCLE
& 137 0.59 3.02 0 0 Up-regulated in serum response of fibroblasts (wound healing)
5 BRCA_PROGNOSIS_NEG
@ 95 0.62 2.98 0 0 Up-regulated in breast tumor cells of negative results (prognosis)
Top five highly enriched pathways are shown. * T cell mediated immune response pathways,
& Serum response related pathway,
@ Gene sets previously known
as bad prognosis. R=rank, P=nominal p-value, FD=FDR q-value.
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-12, and7.4×10
-12 respectively, data shown in
Figure 6). We found that IRF1, who plays a tumor sup-
pressing role, is negatively regulated by competitive
transcriptional binding of IRF2, both of which were sig-
nificantly correlated with tumor stage (p-value 0.001),
depth of tumor infiltration (p-value 0.006) and lymph
node metastasis (p-value 0.015) in human esophageal
cancers [40]. Here, we also suggest that IRF2-IRF1 path-
way is likely to be involved in lymph node invasion and
metastasis progression in human breast cancers with
well-known activities of STAT1 [41-44].
Discussion
In this study, we proposed a monotonically expressed
gene analysis (MEGA) for extracting genes that are
related to lymph node invasion and tumor size in breast
cancer. We analysed expression patterns over a two
dimensional N×T space and provided results of meta-
analysis to evaluate the gene sets. The test has been con-
ducted on completely independent data sets. We showed
that gene sets selected from the suggested LE’ and TE’
functions are strongly correlated with cancer prognoses
including metastasis, relapse and survival, and showed
significantly better results than conventional approaches.
These functions are specially designed to capture expres-
sional differences between two consecutive stages and
consistency of expression patterns as well. The MEGA
model also enabled us to analyze the impact of each clini-
cal factor independently, and to inspect a specific stage
transition in a cancer progression.
Before concluding our report, it is necessary to recon-
sider the meaning of linking clinical factors and cancer
Figure 6 Candidate commonly binding transcription factors. Using Pscan, 50 top-ranked N-MEG+ and N-MEG
0®1+ were analysed in their
upstream sequences. In N-MEG+, transcription factors involved in serum response activities have been identified. In N-MEG
0®1+, IRF1-IRF2
mediated tumor suppressing pathways were identified as candidate driving pathways.
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Page 9 of 14prognosis in a molecular level. A general relationship
among clinical and genetic factors is described in Figure
7. Since a primary tumor first occurred, accumulated
genetic and epigenetic aberrations drive the tumor’s
progression. The relationship between genetic aberra-
tions and gene expression changes or protein function
aberration is strongly established. So it is obvious that
progressed tumors have different gene expressions or
abnormal proteins. In our MEGA analysis, we focused
on the gene expression part. If we found a candidate
gene set which connects gene expression changes and
lymph node invasion (A in Figure 7), it should be able
to explain the relationship to cancer prognosis (C in
Figure 7), because the correlation between lymph node
invasion and cancer prognosis has been firmly proven
(B in Figure 7). We found that previous candidate genes
in A rarely found proper explanations of C. Here, the
meaning of our study is summarized in two points.
First, we tried to improve accuracy in finding candidate
genes in A by interpreting gene expression patterns over
lymph node progression (MEGA). Second, we provided
a credible meta-analysis test procedure to validate the
relationship in C. As there still unexplained important
factors remain, we have to integrate additional data of
other levels to finalize the lymph node invasion related
(or causing) genes. But we suggest the future work also
should be cross-validated in the different types of
relations.
Although the MEGA analysis provided a feasible link
to clinical factors and cancer prognoses in a genetic
Figure 7 Conceptual relationship of clinical and genetic factors. Colors in the box denote different levels of data. Lines are drawn in
different shapes according to different degrees of certainty. After primary tumor occurred, accumulated (epi)genetic mutations drive cancer
progression. With transcriptional level data, we can elucidate lymph node invasion (A) and cancer prognosis (C). But in the prediction steps, the
previously proven relation between D and F should be properly explained (B).
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Page 10 of 14level, some parts remain to be improved. First, the
monotonicity can be defined in various ways. Currently
we can rarely determine the activities of genes in an
absolute expression level. Some genes have higher
saturation level so that the gene expression pattern
might show a monotonic increase through all the clini-
cal stages. On the other hand, if an activity of a gene is
easily saturated, the gene expression pattern above a
certain degree would not be informative anymore.
Handling and determining the optimized pattern on
every gene is almost impossible, but other heuristics will
be available using kinetics and text-mining. Second,
integration with other omics data always count. It is still
a big question; how to connect two different types and
levels of information. As shown in Figure 7, protein
level information explains another big part of clinical
outcomes. In our opinion, those information sets should
be integrated to an augmented ‘gene’ entity with other
available information like point mutations, SNPs, and
CNVs. In this case, the MEGA model has to be revised
in its scoring functions. Lastly, finding for driving
mechanisms of progression is one of the ultimate goals
in this field. We tried to elucidate these mechanisms
through pathway analyses and commonly binding tran-
scription factor analyses here, but it is yet to be a strik-
ing discovery. After we solve the prior questions, our
approach might be more helpful in clarifying the core
genes or genetic events that can be essential in thera-
peutic applications.
Methods
Data sets
Training data sets
We used 278 breast tumor gene expression data from the
expO (expression project for Oncology) database (http://
www.intgen.org/expo.cfm, International Genomics Con-
sortium). The data can be also downloaded from NCBI’s
GEO database (GSE2109). From 2,158 gene expression
profiles for all tissues and tumor types, we chose only
breast carcinomas. Samples without pathological N and
T stage records, or whose pathological M stage and histo-
logical information indicate inclusion of distant metasta-
sis were removed. Finally, the 278 non-metastasis breast
tumor samples were categorized into 16 N×T classes
(N0~N3, T1~T4). We also used seven normal breast
gene expression profiles from GSE3744 [45] to infer the
deviation of each N×T stage against the normal condi-
tion. Normalization of data was processed with the Sim-
pleaffy Package [46] in R by applying RMA normalization
for every N×T stage with normal breast samples. After
normalization, probe sets were collapsed into gene sym-
bols using the GSEA collapse tool [28]. Each gene was
scored by log 2 based fold change.
ONCOMINE data sets for test
For test sets, we used 65 breast cancer data sets from
ONCOMINE database [47]. The 65 data sets were firstly
classified into three major analysis types (Prognosis,
Tumor Stage, and Tumor Grade) each of which is
further classified into matching minor subtypes. Minor
typing has been done by manual inspection. From the
ONCOMINE database, we could download pre-analyzed
tables which include sample size, statistics, and two-
tailed p-values. Two-tailed p-values were further con-
verted into one-tailed p-values.
Monotonically expressed gene analysis (MEGA)
In this work, we use two clinical variables (pathological
T and N), but MEGA can be expanded to three or more
variables with similar procedures. The final goal of the
MEGA analysis is to extract N-wise monotonically
expressed genes (N-MEG) and T-wise monotonically
expressed genes (T-MEG) using monotonicity functions.
W ef i r s td e f i n eat w od i m e n s i o n a lN × Ts p a c ef o re a c h
gene. The N×T space for a gene gy consists of p num-
bers of N stages and q numbers of T stages can be
defined as a (p+1)×(q+1) matrix X:
X() g
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y
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To represent how consistently a series of gene expres-
sions has changed along N and T axes, we defined two
scoring functions of the X matrix:
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where LE is a monotonicity function of gene expres-
sion over lymph node invasion progression and TE is
monotonicity function of gene expression over tumor
size growth. The parameter a is a consistency factor
which emphasizes the direction of gene expression
changes, S is a sign function, and b is a leaping factor
for giving weights to an specific step of stage progres-
sion. The characteristics of parameter a were not
explored in this study. The sign function S is defined
as:
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Page 11 of 14And a matrix of leaping factors b is defined as a
matrix form:
b b =
⎛
⎝
⎜
⎜
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⎞
⎠
⎟
⎟
⎟
−
b
b
10 1
1 1

 
 pp ( )
Because b is only meaningful in two consecutive
stages, the b matrix is much like a diagonal matrix. The
off-diagonal entries are always defined as 1. In this
study, we applied the leaping factors only for N stage
progression.
We can interpret the value of LE and TE functions as
a sum of moving deviations in the course of N and T
stage progression. For each stage, we calculate the gene
expression differences between the current stage and
previous stages from the beginning of stage to the one
step before the current stage. If a certain gene shows a
monotonic increase or decrease in its gene expression
along the N or T stages, the absolute value of the func-
tion would be larger.
Finally the LE and TE functions are normalized by the
overall standard deviation of the X matrix:
LE’(g )
LE(g )
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TE’(g )
TE(g )
(() )
y
y
y
y
=
=
s
s
X
X
g
g
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y
We selected top 40 genes for each monotonicity func-
tion (LE’ and TE’) with their absolute scores. The 40
genes are composed of 20 genes of high score and 20
genes of low score. The genes of high LE’ score means
that the expression of those genes showed monotonic
increase as the lymph node invasion progresses, so the
set of the genes is named N-wise monotonically
expressed genes with positive correlation (N-MEG+).
Similarly, N-wise monotonically expressed genes with
negative correlation (N-MEG-) and two other gene sets
on a tumor size factor (T-MEG+ and T-MEG-) were
defined.
Meta-analysis test on ONCOMINE data set
We performed meta-analysis tests on 65 ONCOMINE
data sets with the selected N-MEG and T-MEG.
Assume that we have a gene set G = {g1,g 2…gn}a n da n
experiment set E = {e1,e 2…ek}. For a gene i and experi-
ment j, we can extract a p-value of gene i in the experi-
ment j from the ONCOMINE data set:
pij =≤ ≤ p-value of gene i in experiment j (for i n, j k)
Because the pij is basically two tailed p-value in the
original data sets, we converted these p-values into one-
tailed p-values:
p
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During this procedure, some genes were missed due to
the different naming strategies and the difference of cover-
age among the test sets. To minimize the loss of informa-
tion, we searched for all aliases and symbols of earlier
versions using the recent version of HUGO Gene Nomen-
clature Committee (HGNC) database (2009/08/23).
Three meta-analysis methods have been applied to calcu-
late overall p-values for a certain set of experiments – Fish-
er’s inverse chi-square [48], Stouffer’s overall Z [49], and
cumulative binomial distribution. Here, the Fisher’si n v e r s e
chi-square method computes a combined statistic using,
Sp ij =− ∏ 2ln( ’)
which follows a c
2distribution with 2nk degrees of
freedom under the joint null hypothesis [50].
Unweighted Stouffer’s Z was calculated by transforming
every p-value into z-score upon the standard normal
distribution, followed by summing up all z values and
dividing by square root of the total numbers:
∀→
=
ℵ
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2
Here, the ℵ is a standard normal distribution, Z is
the sum of all z-values. For the cumulative binomial
method, we first set a threshold to determine whether a
given p-value is significant or not. From the total nk
numbers of p-values, we count the significant p-value
number ns.F o rg i v e nat h r e s h o l dp h, a probability that
one can get a number of p-values equal to or more than
ns incidentally is,
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which can be approximated using incomplete beta
function.
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So, the final p-value is calculated like below.
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Correction of Z scores from background biases
Before finalizing p-values of meta-analyses, we noticed
that the p-values in the ONCOMINE data sets are
upwardly biased. In the 65 studies, 55 studies have big-
ger number of significantly changed genes than we
expected. And we also found that 43 studies have more
up-regulated genes than down-regulated genes. We do
not insist that these results mean experimental errors;
we would rather think it is natural that many of genes
are going to be actively expressed as the cancer pro-
gresses and regulatory mechanisms are being broke
down. But in the case of test procedures, we are likely
to get more false positives unless we consider the back-
ground biases. For example, some random gene sets
may represent ‘more than average’ results and will be
thought to be significant for cancer phenotypes.
To correct the background biases, we generated 1,000
random gene sets (n=20) and tested on the ONCO-
MINE data sets. And we computed Stouffer’so v e r a l lZ
score on each random gene set. Averaged Z scores
represent an expected Z score from a random gene set.
From this result, we could conclude that the meta-ana-
lysis result of gene sets look more up-regulated in the
cancer progression than they really are. So we corrected
all the Stouffer’s Z scores result from N-MEG and T-
MEG by subtracting the mean values of Z in the up-reg-
ulation test and adding in the down-regulation test.
Comparing with previous studies
We first extracted lymph node invasion related gene sets
from previous studies (Suzuki et al [17], Abba et al [18],
and Ellsworth et al [19]). Each gene set was tested using
the corrected Stouffer’s Z test described in previous sec-
tion. We found that the gene set from Abba et al was
already reduced from 300 to 46 genes using eight prog-
nosis experiments. So the Abba set was not used in
further comparisons. We also found there are four
experiments which used expO data set in the ONCO-
MINE test set (Bittner et al). All the overlapping data
was excluded in the test procedure. Additionally, we
selected 40 genes from expO data using two-way
ANOVA and multiple regression models. For each gene,
both models were constructed using ‘aov’ and ‘lm’ func-
tions in R. In ANOVA models, genes were sorted by N
stage dependent two-tailed p-values derived from their
F-statistics because of the model’s non-directionality. In
multiple regression models, 40 genes with the highest P-
values of N stage were selected where their T stage and
interaction terms are not significant. Directions of regu-
lation were determined from the estimated coefficients
(up >0, down <0). Finally five gene sets (N-MEG, multi-
ple regression set, two-way ANOVA set, Suzuki set, and
Ellsworth set) were tested and their p-values were
reported. P-values from meta-analysis were converted
into log-odd score using –log10(P). For each study, the
final score was calculated from adding the two log-odd
scores (from up and down regulated gene sets).
Additional material
Additional File 1: Analysis of enriched GO Term with GOrilla (N-
MEG
0®1). Genes related to N0®N1 stage transition showed significant
over-representation with collagen and extracellular matrix constituent.
Additional File 2: Analysis of enriched GO Term with GOrilla (N-
MEG
2®3). Genes related to N2®N3 stage transition showed significant
over-representation with immune response, wound response and
inflammation.
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